Outset Medical, Inc. (NASDAQ:OM) Given Consensus Rating of “Hold” by Analysts

Outset Medical, Inc. (NASDAQ:OM) has been given an average recommendation of “Hold” by the five brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $10.00.

A number of brokerages recently weighed in on OM. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a report on Wednesday, June 24th. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Finally, Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th.

Insider Activity

In other news, CFO Renee Gaeta sold 17,672 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total transaction of $87,299.68. Following the completion of the sale, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at $561,939.82. This represents a 13.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 25,337 shares of company stock worth $115,660 over the last quarter. 2.50% of the stock is owned by insiders.

Institutional Trading of Outset Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marquette Asset Management LLC purchased a new stake in Outset Medical during the second quarter valued at about $212,000. Renaissance Technologies LLC increased its position in shares of Outset Medical by 391.3% in the first quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock worth $853,000 after acquiring an additional 176,870 shares in the last quarter. Sei Investments Co. raised its holdings in shares of Outset Medical by 15.5% during the first quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock valued at $136,000 after acquiring an additional 4,738 shares during the period. BML Capital Management LLC raised its holdings in shares of Outset Medical by 250.2% during the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after acquiring an additional 1,359,021 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Outset Medical by 4.1% in the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock valued at $239,000 after acquiring an additional 2,435 shares in the last quarter.

Outset Medical Price Performance

Shares of NASDAQ OM opened at $4.20 on Friday. Outset Medical has a twelve month low of $3.00 and a twelve month high of $19.60. The company has a current ratio of 6.29, a quick ratio of 4.97 and a debt-to-equity ratio of 0.87. The firm has a 50-day moving average of $4.46 and a two-hundred day moving average of $4.26. The company has a market capitalization of $77.86 million, a price-to-earnings ratio of -1.01 and a beta of 1.95.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.04). Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%.The business had revenue of $27.86 million during the quarter, compared to analyst estimates of $28.90 million. As a group, analysts expect that Outset Medical will post -3.82 earnings per share for the current fiscal year.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.